HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Robert J. Cerfolio Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Cerfolio, R. J. Articles by Bartolucci, A. A. Search for Related Content PubMed PubMed Citation Articles by Cerfolio, R. J. Articles by Bartolucci, A. A. Related Collections Related Article

Ann Thorac Surg 2004;78:1903-1909
© 2004 The Society of Thoracic Surgeons

---

Original Article: General Thoracic

Repeat FDG-PET After Neoadjuvant Therapy is a Predictor of Pathologic Response in Patients With Non-Small Cell Lung Cancer

^a Department of Surgery, University of Alabama at Birmingham, Birmingham, Alabama, USA and Division of Cardiothoracic Surgery, Department of Surgery, Birmingham Veterans Administration Hospital, Birmingham, Alabama; USA
^b Department of Epidemiology, UAB School of Public Health, Birmingham, Alabama, USA
^c Department of Clinical Pathology, UAB School of Public Health, Birmingham, Alabama, USA
^d Department of Nuclear Medicine, UAB School of Public Health, Birmingham, Alabama, USA
^e Department of Biostatistics, UAB School of Public Health, Birmingham, Alabama, USA

Accepted for publication June 2, 2004.

^* Address reprint requests to Dr Cerfolio, Division of Cardiothoracic Surgery, University of Alabama at Birmingham, 1900 University Blvd, THT 712, Birmingham, AL35294 (E-mail: robert.cerfolio{at}ccc.uab.edu).

	Abstract

Top Abstract Introduction Material and Methods Results Comment References

 
BACKGROUND: Repeat positron emission tomography (PET) with 18F-fluorodeoxyglucose (FDG) and chest computed tomography (CT) are used to assess the effectiveness of chemoradiotherapy in patients with non-small cell lung cancer (NSCLC); however, the change in the standardized uptake values (SUV) has not been correlated with the pathologic change of the primary tumor.

METHODS: This is a retrospective cohort study of a prospective database of 56 patients who had NSCLC, FDG-PET, and chest CT scans both before and after neoadjuvant therapy, followed by complete resection of their cancer. Maximum SUVs (maxSUV) and tumor size were measured, and the percentage of change was compared with the percentage of nonviable tumor cells. The primary objective was to measure the degree of correlation between these values.

RESULTS: The change in the maxSUV has a near linear relationship to the percent of nonviable tumor cells in the resected tumors. FDG-PET's maxSUV is better correlated to pathology than the change in size on CT scan (r² = 0.75, r² = 0.03, p < 0.001). When the maxSUV decreased by 80% or more, a complete pathologic response could be predicted with a sensitivity of 90%, specificity of 100%, and accuracy of 96%.

CONCLUSIONS: The change in maxSUV on FDG-PET scan after neoadjuvant therapy holds a near linear relationship with pathologic response. It is a more accurate predictor than the change of size on CT scan. When the maxSUV decreases by 80% or more it is likely that the patient is a complete responder irrespective of cell type, neoadjuvant treatment, or the final absolute maxSUV. These findings may help guide treatment strategies.

	Introduction

Top Abstract Introduction Material and Methods Results Comment References

 
Lung cancer is the leading cause of cancer deaths worldwide. More Americans die from lung cancer than the next three most common solid organ cancers (breast, prostate, and colon) combined [1–4]. Because of these dismal numbers, more patients are undergoing neoadjuvant therapy before resection, adjuvant therapy after resection, and continued palliative chemotherapy.

Several reports of prospective studies have shown increased survival favoring neoadjuvant therapy for patients with stage Ib, IIa, and N2 (stage IIIa) disease [5–9]. Patients with N2 disease who have had neoadjuvant therapy are usually only considered for resections if the N2 disease resolves. Similarly, further chemotherapy or changes in chemotherapy are often made for those patients with stage IV disease based on response. Improved survival has been shown in patients who have a response, even with stage IV disease [10]. Similarly, patients who are complete responders that undergo resection have a significant survival advantage [11]. Thus, being able to identify responders leads to improved patient selection for surgery and may also help guide further treatment for patients with stage IV disease.

Chest computed tomography (CT) and positron emission tomography (PET) using 18F-fluorodeoxyglucose (FDG) are most often used to assess the response of NSCLC to treatment. However little data have shown that the clinical response rate detected on repeat FDG-PET scan actually correlates with the pathologic response of the primary tumor [12]. Therefore, we evaluated the effectiveness of repeat FDG-PET and repeat CT scan as predictors of this response in a group of patients who met strict entry criteria.

	Material and Methods

Top Abstract Introduction Material and Methods Results Comment References

 
Patients
Over a 24-month period (January 2002 until December 2003), one general thoracic surgeon (RJC) performed 1,963 operations at the University of Alabama at Birmingham (UAB). Ninety-four patients had neoadjuvant therapy before resection, but only 56 met the strict entry criteria described in Table 1. The most common reason for exclusion of the other 38 patients was the lack of a dedicated FDG-PET scan or the lack of a maximum standardized uptake value (maxSUV) reported before the start of their neoadjuvant therapy. The remaining 56 patients comprised the cohort for this study. UAB's Institutional Review Board approved this review of our prospective database. Patients who received neoadjuvant chemotherapy under the guise of the Southern Western Oncology Group S9900 trial received an additional separate consent. Patients were excluded if they had a history of type I diabetes mellitus, had a FDG-PET preformed on a nondedicated camera, did not have the maxSUV reported, had a delay greater than 6 weeks from the completion of their neoadjuvant treatment to resection, had an incomplete resection, were medically unfit, or refused surgery.

The maxSUV was determined by drawing regions of interest (ROI) on the attenuation-corrected FDG-PET images around the primary tumor. It was then calculated by the software contained within the PET-CT scanner by the formula: [13]

(1)

where C = activity at a pixel within the tissue defined by an ROI and ID = injected dose per kg of the patient's body weight (w). The maxSUV within the selected ROI's was used. The percentage of change of the maxSUV was calculated by the formula:

(2)

Patients that had FDG-PET scans performed at outside hospitals were included in this trial if the FDG-PET was performed on a dedicated PET camera with bismuth germanate crystals. All patients were carefully staged and biopsy specimens were taken from all suspicious N2, N3, or M1 areas (maxSUV > 2.5).

Patients with N2 disease had chemoradiotherapy, and those that were N2 negative had chemotherapy alone. Biopsies were performed on all suspicious M1 metastatic lesions unless cancer was suspected in the bone or brain where magnetic resonance imaging (MRI) was considered to be the gold standard. Patients with suspected M1 disease in the liver, adrenal, or contralateral lung underwent definitive biopsy to prove or disprove M1 cancer.

The volume of the tumor on chest CT was calculated using the equation:

(3)

with a, b, and c representing the height, diameter, and width of the mass (cm), respectively. This volume was calculated on the initial chest CT and then on the repeat chest CT after the neoadjuvant therapy was completed. The percentage of change in size was calculated by the formula:

(4)

Surgery
Thoracotomy with complete thoracic lymphadenectomy was performed in all patients in this study. Patients who initially had stage IIIa disease, secondary to N2 disease, in general were offered pulmonary resection only if the initial nodal station involved with cancer was negative for cancer on repeat biopsy after the neoadjuvant therapy was completed. Repeat transesophageal ultrasound with fine needle aspirate was used to reassess lymph node stations 7, 8, and 9, and sometimes 5. Repeat video-assisted thorascopy was used to perform a repeat biopsy of stations 5 and 6. Repeat biopsies were performed on right-sided stations 2 and 4 and left-sided 4 by using open thoracotomy and frozen section analysis. Repeat mediastinoscopy was not performed. Segmentectomy, lobectomy, or pneumonectomy was performed; and wedge resection was not. The bronchial stump was buttressed with an intercostal muscle flap in all patients. As part of the entry criteria for this study, all patients had complete resection with negative margins and complete thoracic lymphadenectomy.

Pathologic Analysis
Multiple hematoxylin and eosin stained sections of each tumor were reviewed by a pathologist and then re-reviewed by another pathologist (TSW) who carefully calculated the percentage of nonviable tumor after recutting the entire tumor and scrutinizing multiple cross-sections. The percent of nonviable tumor was defined as the combined percentage of scar and necrosis. Scar was defined as fibrous tissue intimately admixed with residual tumor. Patients with mixed tumors were labeled as squamous cell or adenocarcinoma based on the predominant cellular type seen. Complete pathologic response was defined as 1% or less of viable tumor cells detected on pathologic review of the entire resected specimens. The pathologists were blinded to all clinical, radiologic, and surgical findings.

Statistical Analysis
The primary outcome evaluated was the degree of correlation between the percentage of change in maxSUV and the percentage of nonviable tumor in the resected specimens. We also evaluated the degree of correlation between the percentages of decrease of the volume of the mass on repeat CT scan and of nonviable tumor in the resected specimen.

In addition, three secondary outcomes were also evaluated. The first was to assess the ability of FDG-PET and CT scan to predict complete pathologic response. The second was to compare the degree of correlation based on the type of neoadjuvant therapy. The third outcome assessed was to compare the degree of correlation based on the two main tissue types of cancer seen in this study, squamous cell and adenocarcinoma.

Spearman's rank-correlation coefficient was used to determine the relationship and establish a linear equation for estimating the percentage of nonviability of tumor according to the percentage of change in the maxSUV on FDG-PET and also the change in volume of the mass on CT scan. Partial correlation coefficients were used to investigate relationships while adjusting for covariates. Multiple linear regression step-wise analysis was used to adjust for risk factors and identify any variables that were independently associated with a decrease in maxSUV (age, gender, percentage of nonviability of tumor, dose of radiation, cell type, and type of neoadjuvant therapy). The highest combined sensitivity and specificity values generated from the receiver operating characteristic (ROC) curves that predicted complete pathologic responders were identified [14]. The ROC curves for FDG-PET and CT were compared according to the method of DeLong and associates [15]. The test for proportions and the binomial approximation test were used to compare the percent accuracy values between FDG-PET and CT scan. A two-sided p value of 0.05 or less was considered to indicate statistical significance. SAS version 9.0 (SAS Institute, Cary, NC) was used to conduct this analysis.

	Results

Top Abstract Introduction Material and Methods Results Comment References

 
Patient Characteristics
There were 56 patients (31 men) with a median age of 63 (range 42 to 76). Patient characteristics are shown in Table 2. Thirty-three patients had chemotherapy alone, and 23 patients with stage Ib, IIa, or non-N2 IIIa were enrolled in the Southern Western Oncology Group S9900 trial. All received carboplatin and paclitaxel. In addition, 5 other patients without N2 disease received chemotherapy alone at outside institutions. Three of these patients had carboplatin and paclitaxel. Twenty-three patients with N2 disease underwent combined chemoradiotherapy, 18 of whom had carboplatin and paclitaxel. The dose of radiotherapy used was 45 to 51 Gy in 8 patients and 60 to 68 Gy in 15 patients. The median dose of preoperative radiation was 60 Gy (range 45 to 68 Gy). There was one operative death (1.8%) and no bronchopleural fistulas.

View larger version (22K): [in this window] [in a new window]   Fig 1. Correlation between the decrease in maximum standardized uptake value (maxSUV) and the percentage of nonviable tumor in the resected specimens. The regression line equation: y = 0.9501 x +5.230; r2 = 0.75, p < 0.001. Values where more than one data point was observed have been indicated by a solid black box and the number of observations are indicated in parenthesis. The open boxes represent one data point. Dashed lines indicate the 95% confidence interval for the regression line (solid line).

View larger version (33K): [in this window] [in a new window]   Fig 2. Receiver operating characteristic curves of sensitivity (solid lines) plotted against 100 minus specificity for 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) and computed tomography (CT) for complete responders. (Area under curve = 0.935 for FDG-PET and 0.532 for CT, p < 0.001).

Cell Type
We found that FDG-PET was better able to predict the pathologic response in patients who had squamous cell cancer than in those that had adenocarcinoma (r² = 0.83 and 0.58, respectively; p < 0.001). Interestingly, we also found that those with squamous cell cancer had a better response to their neoadjuvant therapy. The median decrease in maxSUV was 80% in patients with squamous cell cancer, and the median nonviable tumor found on pathologic examination was 88%. In contrast, the median decrease in maxSUV in patients with adenocarcinoma was 60%, and the median nonviable tumor found on pathologic examination for adenocarcinoma was 69%.

	Comment

Top Abstract Introduction Material and Methods Results Comment References

 
Many studies have demonstrated the problem of false-positive and false-negative results with FDG-PET scans in patients with NSCLC and the problems of restaging [16–24]. One recurring theme is that FDG-PET scans do not supplant the need for tissue biopsy specimens. We, along with others, have shown that a repeat FDG-PET scan may accurately predict the status of lymph nodes after neoadjuvant therapy [16, 24]; however, few reports have shown that repeat FDG-PET is an accurate predictor of the pathologic response of the primary tumor [12, 24, 25]. Nevertheless, it is commonly ordered, and the results are frequently used to guide, change, or even deny subsequent chemoradiotherapy or surgery, or both.

This trial featured stringent entry criteria on a consecutive series of patients and showed that the change in maxSUV on a repeat FDG-PET scan is an accurate predictor of the pathologic response. The strength of this study, compared with other reports, is the entry criteria applied. For example, Ryu and colleagues in 2002 [24] retrospectively studied 26 patients and found that the change in SUVs of the primary tumor was useful for monitoring the therapeutic effect of neoadjuvant chemoradiotherapy in patients with NSCLC. Akhurst and colleagues in 2002 [25] reported a retrospective series on 56 patients and found that FDG-PET after induction therapy accurately detected residual viable primary tumor. However, those reports did not require a baseline FDG-PET to show the percentage of change in maxSUV, a dedicated FDG-PET scan, or a separate tumor type analysis, as was done in our study.

A limitation of our study is the short follow-up period and thus the lack of survival data. Yet others have shown that a significant response rate does equate to improved survival [10, 11]. Further studies with long-term analysis are required.

The ability to noninvasively identify complete responders to neoadjuvant therapy could have important implications for surgical selection. Pisters and colleagues showed in 1993 [11] that the 5-year survival of patients who underwent resection and who had a complete pathologic response was 54% compared with 15% in those without a complete pathologic response. Nineteen (35%) patients in the study were complete responders, a similar incidence reported by Ryu and colleagues [24].

We found that when the maxSUV decreases by more than 80%, a complete responder can be predicted with 96% accuracy. In contrast, Port and colleagues [12] reported in 2004 that repeat PET did not predict the response to neoadjuvant therapy. However, in that report the authors arbitrarily defined a major PET response as a "reduction in the SUV of 50% or more." If they had chosen a percentage of change of 80% or greater in maxSUV instead of 50% for their data they would have found that repeat PET correctly predicted 4 out of the 5 complete responders in their series.

Importantly, we have demonstrated that the maxSUV does not need to fall to 0 to imply a complete responder, but rather it needs to have an 80% or greater reduction. In those patients who had preoperative chemotherapy, 7 patients were complete responders and in 5, the repeat maxSUV fell to 0. However, in the 12 complete responders who received combined chemoradiotherapy, only 6 had a maxSUV of 0 on the repeat FDG-PET. Thus, a patient who is a complete responder may have a maxSUV on the repeat FDG-PET greater than 0, especially if the patient had preoperative radiation. The percentage of drop is the best predictor of complete pathologic response and not the absolute value of the maxSUV on the repeat FDG-PET scan.

One potential concern is that the SUV measured on one PET scanner may be different on another. The term standardized uptake value used to be an oxymoron because it was anything but standardized. However, most all dedicated PET scanners now use software packages that automatically calculate the maxSUV and take into account many of the various factors that can affect its value. Moreover, protocols for PET scanning are become more standardized, and centers are starting to use similar techniques of scanning, dosages of FDG, time intervals from injection to scanning, and baseline glucose, among others. These steps will make SUVs standardized across centers and continents. To protect for this potential problem in this study, we required that the patients received both FDG-PET scans at the same center using similar techniques. Finally, we chose to look at maxSUV instead of mean SUV because it eliminates many of the subjective measurements inherent to the latter.

Interestingly we found that FDG-PET was less accurate for determining the pathologic response after neoadjuvant therapy when patients had radiation in addition to chemotherapy as opposed to chemotherapy alone. Other studies have demonstrated that radiation can interfere with the interpretation of FDG-PET scans [26]. We also found that the FDG-PET after neoadjuvant therapy was a more accurate predictor of response in patients who had squamous cell cancers than those who had adenocarcinoma, but the reasons for this are unclear.

Our report shows that the percentage of change in the maxSUV on FDG-PET scan after neoadjuvant treatment is an accurate predictor of the actual pathologic response of the primary tumor in patients with NSCLC and that it also can identify complete responders. It is more accurate than CT scan. This information may help guide subsequent treatment strategies for medical oncologists, radiation oncologists, and surgeons. Although, this study and our conclusions must obviously be confined to patients with NSCLC, some of its findings may be applicable to patients with other types of solid organ cancers, especially ones that feature squamous cell or adenocarcinoma. Further prospective trials with long-term follow-up are needed.

	References

Top Abstract Introduction Material and Methods Results Comment References

1. Weir HK, Thun MJ, Hankey BF, et al. Annual report to the nation on the status of cancer, 1975–2000, featuring the uses of surveillance data for cancer prevention J Nat Cancer Ins 2003;95(17):1276-1299.
2. Jemal A, Murray T, Samuels A, et al. Cancer statistics, 2003 CA Cancer J Clin 2003;53:5-26.[Abstract/Free Full Text]
3. Parkin DM, Pisani P, Ferlay J. Estimates of the worldwide incidence of eighteen major cancers in 1985 Int J Cancer 1993;54:594-606.[Medline]
4. Spira A, Ettinger DS. Multidisciplinary management of lung cancer N Engl J Med 2004;3550:379-392.
5. Depierre A, Milleron B, Moro-Sibilot, D, et al. Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage 1 (except T1N0), II and IIIa non-small cell lung cancer J Clin Oncol 2002;20:247-253.[Abstract/Free Full Text]
6. Roth JA, Fossella F, Komaki R, et al. A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer J Natl Cancer Inst 1994;86(9):673-680.[Abstract/Free Full Text]
7. Roth JA, Atkinson EN, Fossella F, et al. Long-term follow-up of patients enrolled in a randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer Lung Cancer 1998;21(1):1-6.[Medline]
8. Rosell R, Gomez-Codina J, Camps C, et al. Preresectional chemotherapy in stage IIIA non-small-cell lung cancer: a 7-year assessment of a randomized controlled trial Lung Cancer 1999;26(1):7-14.[Medline]
9. Rosell R, Gomez-Codina J, Camps C, et al. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer N Engl J Med 1994;330:153-158.[Abstract/Free Full Text]
10. Weber WA, Petersen V, Schmidt B, et al. Positron emission tomography in non-small-cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use J Clin Oncol 2003;21(14):2651-2657.[Abstract/Free Full Text]
11. Pisters KM, Ginsberg RJ, Giroux DJ, et al. Induction chemotherapy before surgery for early-stage lung cancer: a novel approachBimodality Lung Oncology Team. J Thorac Cardiovasc Surg 2000;119(3):429-439.[Abstract/Free Full Text]
12. Port JL, Kent MS, Korst RJ, Keresztes R, Levin MA, Altorki NK. Positron emission tomography scanning poorly predicts response to preoperative chemotherapy in non-small cell lung cancer Ann Thorac Surg 2004;77(1):254-259.[Abstract/Free Full Text]
13. Nabi HA, Zubeldia JM. Clinical applications of F18-FDG in oncology J Nucl Med Technol 2002;30:3-9.[Abstract/Free Full Text]
14. Grunkemeier GL, Jin R. Receiver operating characteristic curve analysis of clinical risk models Ann Thorac Surg 2001;72:323-326.[Abstract/Free Full Text]
15. DeLong ER, DeLong DM, Clark-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves; a nonparametric approach Biometrics 1988;44:837-845.[Medline]
16. Cerfolio RJ, Ojha B, Mukherjee S, et al. Positron emission tomography scanning with 2-fluoro-2-deoxy-d-glucose as a predictor of response of neoadjuvant treatment for non-small cell carcinoma J Thorac Cardiovasc Surg 2003;125(4):938-944.[Abstract/Free Full Text]
17. Cerfolio RJ, Buddhiwardhan O, Bryant AS, et al. The role of FDG-PET scan in staging patients with non-small cell carcinoma Ann Thorac Surg 2003;76:861-866.[Abstract/Free Full Text]
18. Gupta NC, Graeber GM, Bishop HA, et al. Comparative efficacy of positron emission tomography with fluorodeoxyglucose in evaluation of small, intermediate, and large lymph node lesions Chest 2000;117:773-778.[Abstract/Free Full Text]
19. Roberts PF, Follette DM, von Haag D, et al. Factors associated with false-positive staging of lung cancer by positron emission tomography Ann Thorac Surg 2000;70:1154-1160.[Abstract/Free Full Text]
20. Pieterman RM, van Putten JW, Meuzelaar JJ, et al. Preoperative staging of non-small cell lung cancer with positron-emission tomography N Engl J Med 2000;343:254-261.[Abstract/Free Full Text]
21. Vansteenkiste JF, Stroobants SG, Dupont PJ, et al. Prognostic importance of the standardized uptake value on (18)F-fluoro-2-deoxy-glucose-positron emission tomography scan in non-small-cell lung cancer: an analysis of 125 casesLeuven Lung Cancer Group. J Clin Oncol 1999;17(10):3201-3206.[Abstract/Free Full Text]
22. Galetta D, Cesario A, Margaritora S, et al. Enduring challenge in the treatment of nonsmall cell lung cancer with clinical stage IIIB: results of a trimodality approach Ann Thorac Surg 2003;76:1802-1809.[Abstract/Free Full Text]
23. Rusch VW, Giroux DJ, Kraut MJ, et al. Induction chemoradiation and surgical resection for non-small cell lung carcinomas of the superior sulcus: initial results of Southwest Oncology Group Trial 9416 (Intergroup Trial 0160) J Thorac Cardiovasc Surg 2001;121(3):472-483.[Abstract/Free Full Text]
24. Ryu J, Choi NC, Fischman AJ, et al. FDG-PET in staging and restaging non-small cell lung cancer after neoadjuvant chemoradiotherapy: correlation with histopathology Lung Cancer 2002;35:179-187.[Medline]
25. Akhurst T, Downey RJ, Ginsberg MS, et al. An initial experience with FDG-PET in the imaging of residual disease after induction therapy for lung cancer Ann Thor Surg 2002;73(1):259-264.[Abstract/Free Full Text]
26. Haberkorn U, Strauss LG, Dimitrakopoulou A, et al. PET studies of fluorodeoxyglucose metabolism in patients with recurrent colorectal tumors receiving radiotherapy J Nucl Med 1991;32(8):1485-1490.[Abstract/Free Full Text]

This article has been cited by other articles:

				T. Tanvetyanon, E. A. Eikman, E. Sommers, L. Robinson, D. Boulware, and G. Bepler Computed Tomography Response, But Not Positron Emission Tomography Scan Response, Predicts Survival After Neoadjuvant Chemotherapy for Resectable Non-Small-Cell Lung Cancer J. Clin. Oncol., October 1, 2008; 26(28): 4610 - 4616. [Abstract] [Full Text] [PDF]

				C. Dooms, E. Verbeken, S. Stroobants, K. Nackaerts, P. De Leyn, and J. Vansteenkiste Prognostic Stratification of Stage IIIA-N2 Non-Small-Cell Lung Cancer After Induction Chemotherapy: A Model Based on the Combination of Morphometric-Pathologic Response in Mediastinal Nodes and Primary Tumor Response on Serial 18-Fluoro-2-Deoxy-Glucose Positron Emission Tomography J. Clin. Oncol., March 1, 2008; 26(7): 1128 - 1134. [Abstract] [Full Text] [PDF]

				B. H.L. Goulart, J. W. Clark, H. H. Pien, T. G. Roberts, S. N. Finkelstein, and B. A. Chabner Trends in the Use and Role of Biomarkers in Phase I Oncology Trials Clin. Cancer Res., November 15, 2007; 13(22): 6719 - 6726. [Abstract] [Full Text] [PDF]

				R. J. Cerfolio and A. S. Bryant When is it Best to Repeat a 2-Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography/Computed Tomography Scan on Patients with Non-Small Cell Lung Cancer Who Have Received Neoadjuvant Chemoradiotherapy? Ann. Thorac. Surg., October 1, 2007; 84(4): 1092 - 1097. [Abstract] [Full Text] [PDF]

				L.-F. de Geus-Oei, H. F.M. van der Heijden, E. P. Visser, R. Hermsen, B. A. van Hoorn, J. N.H. Timmer-Bonte, A. T. Willemsen, J. Pruim, F. H.M. Corstens, P. F.M. Krabbe, et al. Chemotherapy Response Evaluation with 18F-FDG PET in Patients with Non-Small Cell Lung Cancer J. Nucl. Med., October 1, 2007; 48(10): 1592 - 1598. [Abstract] [Full Text] [PDF]

				F.-M. S. Kong, K. A. Frey, L. E. Quint, R. K. T. Haken, J. A. Hayman, M. Kessler, I. J. Chetty, D. Normolle, A. Eisbruch, and T. S. Lawrence A Pilot Study of [18F]Fluorodeoxyglucose Positron Emission Tomography Scans During and After Radiation-Based Therapy in Patients With Non Small-Cell Lung Cancer J. Clin. Oncol., July 20, 2007; 25(21): 3116 - 3123. [Abstract] [Full Text] [PDF]

				R. J. Cerfolio and A. S. Bryant Ratio of the Maximum Standardized Uptake Value on FDG-PET of the Mediastinal (N2) Lymph Nodes to the Primary Tumor May Be a Universal Predictor of Nodal Malignancy in Patients With Nonsmall-Cell Lung Cancer Ann. Thorac. Surg., May 1, 2007; 83(5): 1826 - 1830. [Abstract] [Full Text] [PDF]

				C. Nahmias, W. T. Hanna, L. M. Wahl, M. J. Long, K. F. Hubner, and D. W. Townsend Time Course of Early Response to Chemotherapy in Non-Small Cell Lung Cancer Patients with 18F-FDG PET/CT J. Nucl. Med., May 1, 2007; 48(5): 744 - 751. [Abstract] [Full Text] [PDF]

				H. Kuehl, P. Veit, S. J. Rosenbaum, A. Bockisch, and G. Antoch Can PET/CT Replace Separate Diagnostic CT for Cancer Imaging? Optimizing CT Protocols for Imaging Cancers of the Chest and Abdomen J. Nucl. Med., January 1, 2007; 48(1_suppl): 45S - 57S. [Abstract] [Full Text] [PDF]

				R. J. Cerfolio, A. S. Bryant, E. Scott, M. Sharma, F. Robert, S. A. Spencer, and R. I. Garver Women With Pathologic Stage I, II, and III Non-small Cell Lung Cancer Have Better Survival Than Men Chest, December 1, 2006; 130(6): 1796 - 1802. [Abstract] [Full Text] [PDF]

				M. B. Lobrano Partnerships in Oncology and Radiology: The Role of Radiology in the Detection, Staging, and Follow-up of Lung Cancer Oncologist, July 1, 2006; 11(7): 774 - 779. [Abstract] [Full Text] [PDF]

				R. J. Cerfolio, A. S. Bryant, and B. Ojha Restaging patients with N2 (stage IIIa) non-small cell lung cancer after neoadjuvant chemoradiotherapy: A prospective study J. Thorac. Cardiovasc. Surg., June 1, 2006; 131(6): 1229 - 1235. [Abstract] [Full Text] [PDF]

				C. Pottgen, S. Levegrun, D. Theegarten, S. Marnitz, S. Grehl, R. Pink, W. Eberhardt, G. Stamatis, T. Gauler, G. Antoch, et al. Value of 18F-Fluoro-2-Deoxy-D-Glucose-Positron Emission Tomography/Computed Tomography in Non-Small-Cell Lung Cancer for Prediction of Pathologic Response and Times to Relapse after Neoadjuvant Chemoradiotherapy Clin. Cancer Res., January 1, 2006; 12(1): 97 - 106. [Abstract] [Full Text] [PDF]

				F. Barlesi, C. Doddoli, J.-P. Torre, R. Giudicelli, P. Fuentes, P. Thomas, and P. Astoul Comparative prognostic features of stage IIIAN2 and IIIB non-small-cell lung cancer patients treated with surgery after induction therapy Eur. J. Cardiothorac. Surg., October 1, 2005; 28(4): 629 - 634. [Abstract] [Full Text] [PDF]

				B. Milleron, V. Westeel, E. Quoix, D. Moro-Sibilot, D. Braun, B. Lebeau, A. Depierre, and for the French Thoracic Cooperative Group Complete Response Following Preoperative Chemotherapy for Resectable Non-Small Cell Lung Cancer: Accuracy of Clinical Assessment Using the French Trial Database Chest, September 1, 2005; 128(3): 1442 - 1447. [Abstract] [Full Text] [PDF]

				R. J. Cerfolio, A. S. Bryant, B. Ohja, and A. A. Bartolucci The maximum standardized uptake values on positron emission tomography of a non-small cell lung cancer predict stage, recurrence, and survival J. Thorac. Cardiovasc. Surg., July 1, 2005; 130(1): 151 - 159. [Abstract] [Full Text] [PDF]

				R. J. Cerfolio, A. S. Bryant, B. Ohja, A. A. Bartolucci, and M. A. Eloubeidi The accuracy of endoscopic ultrasonography with fine-needle aspiration, integrated positron emission tomography with computed tomography, and computed tomography in restaging patients with esophageal cancer after neoadjuvant chemoradiotherapy J. Thorac. Cardiovasc. Surg., June 1, 2005; 129(6): 1232 - 1241. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Robert J. Cerfolio Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Cerfolio, R. J. Articles by Bartolucci, A. A. Search for Related Content PubMed PubMed Citation Articles by Cerfolio, R. J. Articles by Bartolucci, A. A. Related Collections Related Article